8-K: Milestone Pharmaceuticals Announces Positive Real-World Data for Etripamil in PSVT Treatment

Milestone Pharmaceuticals released new clinical data demonstrating the effectiveness of etripamil in self-managing recurrent paroxysmal supraventricular tachycardia (PSVT) episodes.

Summary

• Milestone Pharmaceuticals has announced new clinical data for etripamil, an investigational drug, showing its effectiveness in real-world settings for treating recurrent PSVT.
• The study, known as NODE-303, was an open-label Phase 3 trial conducted in North and South America, evaluating self-administered etripamil (70 mg nasal spray) for multiple PSVT episodes.
• The results showed that symptom-prompted treatment with etripamil was effective at restoring normal heart rhythm (sinus rhythm) compared to placebo, with a median time-to-conversion of 17.0 minutes.
• The study also found that the conversion rate of PSVT to sinus rhythm was consistent across multiple episodes, and the frequency of adverse events decreased with successive episodes.
• Efficacy of etripamil for PSVT conversion was 60% by 30 minutes and 69.9% by 60 minutes after self-administration, which is similar to previous studies.
• The study included patients with a history of co-morbid atrial fibrillation (AFib) or atrial flutter, and the protocol was amended to allow a repeat dose if symptoms persisted after 10 minutes.

Sentiment

Score: 7

Explanation: The document presents positive clinical data for etripamil, suggesting a potential improvement in PSVT treatment. However, there are still risks associated with regulatory approval and market conditions.

Positives

• Etripamil allows patients to self-manage PSVT episodes, potentially reducing the need for emergency room visits.
• The drug showed consistent efficacy across multiple PSVT episodes.
• The time to conversion to sinus rhythm was relatively quick at a median of 17 minutes.
• Adverse events were primarily localized to the nasal administration site and decreased with repeated use.
• The study included a broad patient population, including those with co-morbid conditions like AFib.

Negatives

• Adverse events were reported, although primarily localized to the nasal administration site.
• The efficacy rate of 69.9% at 60 minutes means that a significant portion of patients did not achieve conversion within that timeframe.

Risks

• The approval of etripamil by the FDA is not guaranteed and may require additional trials or data.
• There are risks inherent in biopharmaceutical product development and clinical trials, including regulatory approval processes.
• The company's ability to raise additional capital in the current economic climate is a risk.
• General economic, political, and market conditions could impact the company's performance.

Future Outlook

The company is seeking regulatory approval for etripamil and believes it has the potential to significantly shift the management approach for recurrent PSVT. However, the approval process is subject to risks and uncertainties.

Management Comments

• David Bharucha, MD, PhD, FACC, Chief Medical Officer of Milestone Pharmaceuticals, stated that the data demonstrates patients' ability to self-manage multiple episodes of PSVT with etripamil.
• He also noted that the data, combined with prior Phase 3 studies, completes an exceptionally large data package assessing acute treatment of PSVT in the at-home setting.

Industry Context

This announcement is significant as it addresses the unmet need for effective and convenient treatments for PSVT, a common heart rhythm disorder. The ability for patients to self-administer treatment at home could reduce the burden on emergency departments and improve patient quality of life.

Comparison to Industry Standards

• The study's results, with a 69.9% conversion rate at 60 minutes, are comparable to other treatments for PSVT, including those administered in a clinical setting.
• The self-administration aspect of etripamil is a key differentiator compared to traditional treatments that often require medical supervision.
• The inclusion of patients with co-morbid conditions like AFib is notable, as many PSVT treatments may not be suitable for this population.
• The study's open-label design is a common approach in Phase 3 trials, but the results are consistent with previous double-blinded studies, increasing confidence in the findings.

Stakeholder Impact

• Shareholders may view the positive clinical data favorably.
• Patients with PSVT may benefit from a new self-administered treatment option.
• Healthcare providers may have a new tool to manage PSVT, potentially reducing emergency room visits.
• Employees of Milestone Pharmaceuticals may be impacted by the success or failure of the drug's approval.

Next Steps

• Milestone Pharmaceuticals will continue to pursue regulatory approval for etripamil.
• The company will make the presentation and publication available on its corporate website.

Key Dates

Keywords

etripamil, PSVT, paroxysmal supraventricular tachycardia, cardiovascular, arrhythmia, sinus rhythm, clinical trial, self-administration, NODE-303, Milestone Pharmaceuticals